Source comparison
Melanotan-1 50s Age Specific Protocol: Comparison Table
The following table compares standard Melanotan-1 protocols designed for younger adults (ages 25–40) with the modified protocol appropriate for individuals over 50. These differences reflect pharmacokinetic changes, cardiovascular considerations, and realistic
This comparison does not assign a generated winner or score.
- The following table compares standard Melanotan-1 protocols designed for younger adults (ages 25–40) with the modified protocol appropriate for individuals over 50. These differences reflect pharmacokinetic changes, cardiovascular considerations, and realistic melanogenesis timelines at different ages.
- Starting Dose
- 0.5–1mg daily
- 0.25mg daily
- Reduced renal clearance extends half-life by 40–55% in older adults
- Halving the starting dose prevents plasma accumulation that triggers cardiovascular strain
- Dose Escalation Interval
- 5–7 days
- 10–14 days
- Slower escalation allows blood pressure response assessment at steady-state levels
- Essential safety measure. BP peaks lag dose increases by 3–5 days in older users
- Typical Maintenance Dose
- 1–2mg daily
- 0.5–0.75mg daily
- Lower eGFR means lower doses produce equivalent receptor occupancy
- Not underdosing. Adjusted for actual pharmacokinetics
- Blood Pressure Monitoring
- Optional
- Before each dose increase, then weekly
- MC4R stimulation produces larger BP spikes in individuals with arterial stiffness
- Non-negotiable. Unmonitored use after 50 carries preventable cardiovascular risk
- Expected Timeline to Visible Tan
- 14–21 days
- 28–42 days
- Melanocyte density declines ~8–10% per decade after age 40
- Patience required. Lower melanocyte counts mean slower pigment accumulation
- Renal Function Assessment
- Not required
- Baseline eGFR, recheck every 90 days if <75ml/min
- Peptide clearance depends on kidney function, which declines 20–30% by age 55
- Prevents accumulation in individuals with subclinical CKD